Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer.

[1]  J. Witjes,et al.  Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. , 2005, The Journal of urology.

[2]  I. Stratford,et al.  Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. , 2004, Biochemical pharmacology.

[3]  P. Workman,et al.  The experimental development of bioreductive drugs and their role in cancer therapy , 1993, Cancer and Metastasis Reviews.

[4]  Frank S. Guziec,et al.  The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase , 2002, Cancer Chemotherapy and Pharmacology.

[5]  J. Brown,et al.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9 , 2001, British Journal of Cancer.

[6]  L. Amzel,et al.  Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones. , 2001, Structure.

[7]  P. Workman,et al.  Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. , 2001, Biochemical pharmacology.

[8]  J. Schellens.  Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9 , 2001, Anti-cancer drugs.

[9]  T. Ward,et al.  Influence of extracellular pH on the cytotoxicity and DNA damage of a series of indolequinone compounds. , 2001, Anticancer research.

[10]  J. Hartley,et al.  Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. , 2000, Frontiers in bioscience : a journal and virtual library.

[11]  E. B. Skibo,et al.  Sigmatropic reactions of the aziridinyl semiquinone species. Why aziridinyl benzoquinones are metabolically more stable than aziridinyl indoloquinones. , 2000, Biochemistry.

[12]  A. Harris,et al.  The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. , 2000, Biochemical pharmacology.

[13]  Jos H. Beijnen,et al.  BIOANALYTICAL LIQUID CHROMATOGRAPHIC METHOD VALIDATION. A REVIEW OF CURRENT PRACTICES AND PROCEDURES , 2000 .

[14]  S. Aamdal,et al.  Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG) , 2000, Cancer Chemotherapy and Pharmacology.

[15]  P. Workman,et al.  Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites. , 1998, Biochemical pharmacology.

[16]  J. Cummings,et al.  Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9. , 1998, Biochemical pharmacology.

[17]  P. Workman,et al.  Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. , 1997, British Journal of Cancer.

[18]  R. Phillips.  Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-β-en-α-ol (EO9) by human DT-diaphorase , 1996 .

[19]  A. te Velde,et al.  EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. , 1996, European journal of cancer.

[20]  J. Cummings,et al.  The autoxidation of the reduced forms of EO9. , 1996, Free radical research.

[21]  S. Aamdal,et al.  Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group. , 1996, European journal of cancer.

[22]  A. te Velde,et al.  A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). , 1996, Annals of Oncology.

[23]  G. Peters,et al.  Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. , 1996, General pharmacology.

[24]  J. Double,et al.  EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. , 1995, British Journal of Cancer.

[25]  M. Maliepaard,et al.  Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. , 1995, British Journal of Cancer.

[26]  J. Verweij,et al.  Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. , 1994, Journal of the National Cancer Institute.

[27]  P. Workman,et al.  Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. , 1994, International journal of radiation oncology, biology, physics.

[28]  S. Aamdal,et al.  Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group. , 1994, Oncology research.

[29]  J. Beijnen,et al.  A systematic study on the chemical stability of the novel indoloquinone antitumour agent EO9 , 1993 .

[30]  J. Verweij,et al.  Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine. , 1993, Journal of chromatography.

[31]  J. Double,et al.  Potentiation of EO9 anti-tumour activity by hydralazine. , 1993, European journal of cancer.

[32]  J. Double,et al.  EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. , 1993, European journal of cancer.

[33]  J. Double,et al.  Factors affecting the in vitro dissolution of cobalt oxide. , 1992, British Journal of Cancer.

[34]  P. Workman,et al.  Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. , 1992, International journal of radiation oncology, biology, physics.

[35]  P. Workman,et al.  Gradient high-performance liquid chromatographic assay for the determination of the novel indoloquinone antitumour agent E09 in biological specimens. , 1990, Journal of chromatography.